FDA Determines Regulatory Review Period for PREVICOX Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of PREVICOX, a medication, in accordance with federal regulations. This decision was prompted by a formal application submitted to the Director of Patents and Trademarks at the US Department of Commerce.